Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

28.12 -0.20 (-0.69%)
Streaming Delayed Price Updated: 3:56 PM EDT, Oct 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 858,892
Open 28.34
Bid (Size) 28.12 (8)
Ask (Size) 28.13 (3)
Prev. Close 28.32
Today's Range 28.00 - 28.79
52wk Range 19.12 - 29.75
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 No-Brainer Stock to Buy With $40
The midcap biotech just became an even better buy. 
Via The Motley Fool
Analyst Ratings For Exelixis
Via Benzinga

Performance

YTD
+17.53%
+17.53%
1 Month
+6.70%
+6.70%
3 Month
+25.84%
+25.84%
6 Month
+18.62%
+18.62%
1 Year
+43.42%
+43.42%

More News

Read More
Navigating 16 Analyst Ratings For Exelixis
Via Benzinga
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
Key Takeaways From Exelixis Analyst Ratings
Via Benzinga
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
Via Talk Markets
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
2 Growth Stocks to Buy With Less Than $100
Via The Motley Fool
A Closer Look at 5 Analyst Recommendations For Exelixis
Via Benzinga
NASDAQ:EXEL, an undervalued stock with good fundamentals.
Via Chartmill
Expert Outlook: Exelixis Through The Eyes Of 5 Analysts
Via Benzinga
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
From Exelixis, Inc.
Via Business Wire
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
From Exelixis, Inc.
Via Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
3 Stocks to Buy for a Soft Landing, If There Is One
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
Via Benzinga
Exposures Product Safety
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
Via Benzinga
Topics Stocks
Exposures US Equities
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.